LONG PROGRESSIVE FREE SURVIVAL TO PACLITAXEL AND CISPLATIN IN FIRST LINE IS ASSOCIATED WITH BETTER RESPONSE AND PROGRESSION FREE SURVIVAL TO DOCETAXEL IN SECOND LINE IN ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
作者：
Macedo, Eleazar O. [1 ]
Arrieta, Oscar [1 ]
Orta, David [1 ]
机构：
[1] Inst Nacl Cancerol, Mexico City, DF, Mexico
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
NSCLC; metastasis; Interval free paclitaxel; response toDocetaxel;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.10-055
引用
收藏
页码：S1182 / S1182
页数：1
相关论文
共 50 条
  • [1] Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
    Aboshi, Masayuki
    Kaneko, Masayuki
    Narukawa, Mamoru
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (05) : 839 - 848
  • [2] Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
    Aboshi, Masayuki
    Kaneko, Masayuki
    Narukawa, Mamoru
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (05) : 839 - 848
  • [3] Modified, weekly dosing with docetaxel and cisplatin as first-line therapy in advanced non-small cell lung cancer
    Hsiao, Shih-Chuan
    Su, Wu-Chou
    NATIONAL MEDICAL JOURNAL OF INDIA, 2009, 22 (02) : 67 - 69
  • [4] Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI
    Liu, Yu-Tao
    Zhang, Kai
    Li, Cheng-Cheng
    Hu, Xing-Sheng
    Jiang, Jun
    Hao, Xue-Zhi
    Wang, Yan
    Li, Jun-Ling
    Xing, Pu-Yuan
    Yang, Sheng
    Zhang, Xin
    Wang, Guo-Qiang
    Cai, Shang-Li
    Shi, Yuan-Kai
    JOURNAL OF CANCER, 2019, 10 (21): : 5108 - 5113
  • [5] A Progression Free Survival Score for EGFR Mutant Non-Small Cell Lung Cancer Patients Treat with First Line EGFR Tyrosine Kinase Inhibitors
    Chen, Yu-Mu
    Lin, Meng-Chih
    Fang, Wen-Feng
    Lie, Chien-Hao
    Chang, Huang-Chih
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S276 - S277
  • [6] Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
    Chiu, Li-Chung
    Hsu, Ping-Chih
    Wang, Chin-Chou
    Ko, How-Wen
    Kuo, Scott Chih-Hsi
    Ju, Jia-Shiuan
    Tung, Pi-Hung
    Huang, Allen Chung-Cheng
    Yang, Cheng-Ta
    THORACIC CANCER, 2024, 15 (07) : 529 - 537
  • [7] Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer
    Cucevic, B
    Samarzija, M
    Baricevic, D
    Jakopovic, M
    Redzepi, G
    Samija, M
    COLLEGIUM ANTROPOLOGICUM, 2005, 29 (02) : 583 - 588
  • [8] A Phase II Study of Weekly Docetaxel-Cisplatin As First-Line Treatment for Advanced Non-small Cell Lung Cancer
    Binder, Daniel
    Hackenthal, Matthias
    Graseck, Lutz
    Schweisfurth, Hans
    Schaeper, Christoph
    Kruell, Matthias
    Temmesfeld-Wollbrueck, Bettina
    Suttorp, Norbert
    Suttorp, Thomas
    Beinert, Thomas
    Hellriegel, Klaus-Peter
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : 1144 - 1147
  • [9] BIWEEKLY CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER
    Benekli, Mustafa
    Gunaydin, Yusuf
    Inanc, Mevlude
    Ozkan, Metin
    Demirci, Ayse
    Demirci, Umut
    Suner, Ali
    Karaca, Halit
    Tonyali, Onder
    Berk, Veli
    Buyukberber, Suleyman
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S563 - S563
  • [10] Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
    Yamamoto, Takaya
    Tsukita, Yoko
    Katagiri, Yu
    Matsushita, Haruo
    Umezawa, Rei
    Ishikawa, Yojiro
    Takahashi, Noriyoshi
    Suzuki, Yu
    Takeda, Kazuya
    Miyauchi, Eisaku
    Saito, Ryota
    Katsuta, Yoshiyuki
    Kadoya, Noriyuki
    Jingu, Keiichi
    BMC CANCER, 2022, 22 (01)
12345